SYMBYAX
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMBYAX is an oral capsule combination product approved by Eli Lilly in December 2003. The exact mechanism of action and indications are not specified in available data, but it represents a small-molecule therapeutic approach. It is currently in the loss-of-exclusivity approaching phase of its product lifecycle.
$0.065BPart D
LOE ApproachingMature product with minimal market spending ($65K in 2023) and declining patient volume; brand team likely operating in sustainment mode with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMBYAX presents limited career growth opportunity with zero linked job openings and minimal commercial activity ($65K spending, 134 claims). This is a mature, declining product suitable for early-career professionals seeking stability or experienced managers skilled in lifecycle management and generic defense strategies.
Brand ManagerMedical Science Liaison
Worked on SYMBYAX at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.